Roche has agreed to invest 710 billion won over five years in South Korea’s pharmaceutical and biotech sector under a memorandum of understanding (MOU) signed with the country’s Ministry of Health and Welfare. The investment, equivalent to roughly 480–520 million U.S. dollars depending on the exchange rate referenced in various reports, is aimed at expanding clinical trials, strengthening biopharmaceutical capabilities, and developing local talent. The agreement is part of Seoul’s broader push to position South Korea as a leading hub for global clinical research and advanced biomedicine.
Under the MOU, Roche is expected to increase the number and scale of clinical trials conducted in South Korea and collaborate with domestic partners on research and development activities. The investment will support areas such as oncology and other major therapeutic fields, while also bolstering infrastructure needed for complex, late‑stage trials. South Korean officials said the deal is intended to attract more high-value R&D projects from multinational pharmaceutical companies and enhance the country’s global competitiveness in drug development.
Government statements indicate that a portion of the 710 billion won commitment will go toward nurturing specialized workforce capabilities, including training programs and collaboration with local institutions. By deepening partnerships with South Korean hospitals, research centers, and biotech companies, Roche is expected to help accelerate the development and commercialization of innovative therapies originating from or tested in the country. Observers note that the scale of the pledged investment underscores both South Korea’s strategic importance in global clinical research and Roche’s interest in accessing a large, well-organized patient population and advanced healthcare infrastructure.
The announcement follows South Korea’s continued efforts to attract foreign direct investment in bio-health as a core growth engine, including incentives and regulatory support for multinational R&D projects. Local authorities have framed the Roche MOU as a flagship example of public–private cooperation that can generate high-quality jobs, expand clinical trial opportunities for patients, and reinforce the country’s role in the global pharmaceutical supply and innovation chain.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!